1600 related articles for article (PubMed ID: 28889323)
1. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
Clin Genitourin Cancer; 2017 Jun; 15(3):e437-e446. PubMed ID: 28188047
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
4. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
[TBL] [Abstract][Full Text] [Related]
6. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Ishihara H; Yagisawa T; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
Int J Clin Oncol; 2017 Feb; 22(1):126-135. PubMed ID: 27549785
[TBL] [Abstract][Full Text] [Related]
7. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Gunduz S; Mutlu H; Uysal M; Coskun HS; Bozcuk H
Asian Pac J Cancer Prev; 2014; 15(8):3801-4. PubMed ID: 24870797
[TBL] [Abstract][Full Text] [Related]
9. Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.
Furukawa J; Miyake H; Kusuda Y; Fujisawa M
Int J Clin Oncol; 2015 Apr; 20(2):351-7. PubMed ID: 24894624
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
Zhang HL; Sheng XN; Li XS; Wang HK; Chi ZH; He ZS; Ye DW; Guo J
BMC Cancer; 2017 Jan; 17(1):16. PubMed ID: 28056874
[TBL] [Abstract][Full Text] [Related]
12. Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Chrom P; Stec R; Semeniuk-Wojtas A; Bodnar L; Spencer NJ; Szczylik C
Clin Genitourin Cancer; 2016 Oct; 14(5):457-464. PubMed ID: 26980234
[TBL] [Abstract][Full Text] [Related]
13. Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Kawashima A; Tsujimura A; Takayama H; Arai Y; Nin M; Tanigawa G; Uemura M; Nakai Y; Nishimura K; Nonomura N;
Int J Urol; 2012 Dec; 19(12):1050-7. PubMed ID: 22860625
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
[TBL] [Abstract][Full Text] [Related]
15. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
16. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
[TBL] [Abstract][Full Text] [Related]
17. Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
De Lichtenberg TH; Hermann GG; Rørth M; Højer Larsen MJ; Mansourvar Z; Holm ML; Scheike T
Scand J Urol; 2014 Aug; 48(4):379-86. PubMed ID: 24521185
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
19. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Miyake H; Miyazaki A; Imai S; Harada K; Fujisawa M
Target Oncol; 2016 Apr; 11(2):175-82. PubMed ID: 26341668
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Wang J; Liu L; Qu Y; Xi W; Xia Y; Bai Q; Xiong Y; Long Q; Xu J; Guo J
J Urol; 2016 Nov; 196(5):1363-1370. PubMed ID: 27288695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
